(in,,1)
(TAMs,,1)
(2008,1)
(calculated,1)
(healing,1)
(beliefs,2)
(surgery,2)
(segmenting,1)
(discussion 
Audio,1)
(produced,1)
(9%,1)
(could,10)
(dose(MTD)and,1)
(mastectomies,2)
(evidence,2)
(activity-guided,1)
(isolation,1)
(P<0 0001),2)
(evaluating,1)
(seen,1)
(activation,1)
(controls 
These,1)
(applications,4)
(matching,1)
(used,7)
(response 
The,1)
(15-3),,1)
(modality,2)
((herceptin),1)
(intricately,1)
(specimen,1)
(less,1)
(triple,1)
(time-varying,1)
(indicating,1)
(skin,,1)
(beyond,1)
(mg/m2,1)
(candidates,1)
(nervous,1)
(most,7)
(cancer 
MEDLINE,,1)
(factor ,1)
(recurrences,3)
(all,2)
(IR-B),2)
(trainee],1)
(predictors,1)
(induce,1)
(postoperative,1)
(insulin,2)
(0 630) 
The,1)
(46 34,1)
((n = 25),2)
(recently,1)
(functional,1)
(selection,4)
(endocrine,11)
(81%,1)
(SEER-based,1)
(GEM,3)
(authentication,2)
(signalling,1)
(no-radiotherapy,1)
(is,49)
(settings 
While,1)
(anatomic,1)
(impact,2)
(analysis 
This,1)
(apoptosis-promoting,1)
(cellular,1)
(allowing,1)
(acid 
This,1)
(0 5,1)
(excitement 
It,1)
(175,1)
((RANKL),1)
(273 μm,1)
(women 
Women's,1)
(diagnosis 
TNBC,1)
(polyubiquitination,4)
(discussions,1)
(cells,,2)
(Despite,1)
(escalated,1)
(1,7)
(CXCL1-based,1)
(suggest,1)
(physical,1)
(therapeutics 
Oncolytic,1)
(cutoff,1)
(reversed,1)
(severe,1)
(giving,1)
(simulate,1)
(resection,1)
(suggested,2)
(resistance 
Analysis,1)
(main,1)
(studies,,1)
(electrospray,1)
(data,,1)
(GEM(Level,1)
(TAMs/CXCL1,1)
(fulvestrant-containing,1)
(parameters,5)
(insight,2)
(subtypes,1)
(55,1)
(cancer 
Female,1)
(Sexual,1)
(six,1)
(biopsy,1)
(rim,1)
(﻿Antrodia,1)
((lincRNA-ROR),1)
((TAM),1)
(MRI,7)
(cessation 
This,1)
(investigate,5)
(fibronectin;,1)
(mass,1)
(lesion,2)
(formation,4)
(viruses,4)
(antagonist,,1)
((44 6%),,1)
(suppressed,2)
(guiding,1)
(mammary,2)
(reaction 
RNA,1)
(vital,1)
(system 
Moreover,,1)
(time-efficient,,1)
(67 9%,1)
(Comparison,1)
(RNAs,2)
(estrogen,11)
(substantial,1)
(standard,2)
((IL-1�),1)
(tend,1)
(P=0 077) 
As,1)
(searched,1)
(choosing,1)
(excellent/good,1)
(present,6)
(correlation,4)
(biomarkers,4)
(analysis,9)
(difficult,1)
(characteristics,,1)
(test,1)
(MUC1,,1)
(serving,1)
(cancer,77)
(up,3)
(few,1)
(component,1)
(CSC,2)
(toxicity 
While,1)
(typical,2)
(cells 
Agents,1)
(reducing,2)
(was,56)
(disappeared,1)
(diffuse,2)
(interacting,1)
(communication,1)
(how,1)
(layer,2)
(therapy 
The,2)
(available,,1)
(potential,11)
((nAB),1)
(doses 
A,1)
(cells 
QPCR,1)
(correlated,2)
(recorded,1)
(196,1)
(voxel,,1)
(like,3)
(E3-ubiquitin,1)
(expression 
Furthermore,,1)
(Echinococcus,1)
(combined,3)
(Wnt/β-catenin,1)
(value,1)
(scavenging,,1)
(dimethylthiazolyl-2)-2,,1)
(diagnosis 
BP-treated,1)
(ERα36,1)
(proteins,,2)
(OVs,1)
(lubrication,1)
(recent,2)
(patients 
No,1)
(collect,1)
((MCF10A),1)
(analyzed,1)
(12%,1)
(model,6)
(invasion,1)
(uptake,2)
(mixed,2)
(pathway,5)
(osteoporotic,2)
(continue,2)
(everolimus,1)
(one,5)
(colonization,1)
(Chinese,1)
(oncologist,2)
(worldwide 
It,1)
(NF-κB/SOX4,1)
(426 × 421 × 260 × 559,1)
(ideal,1)
(reconstruction 
Consequently,,1)
((ROS) 
Real-time,1)
(parameters),,1)
(Type,1)
(61 6%,1)
(nonstandardized,1)
(eribulin,1)
(lubrication,,1)
((±,2)
(from,25)
(monoclonal,1)
(irradiation,2)
(tools,,1)
(within,3)
(stage,3)
(5 6,1)
(involved,4)
(two,8)
(derived,1)
(education,1)
(realistic,2)
((HR),1)
(discuss,2)
(HPLC,1)
(site ,1)
(cell-death,1)
(adequate,1)
(large,1)
(coefficient 
The,1)
(sulforhodamine,1)
(antagonism,1)
(oxidative,1)
(age,3)
(possess,1)
(metastases 
The,1)
(kinase,1)
((MDA-MB-231),3)
(statistics,1)
(2014,1)
((defined,1)
(overall,5)
(antigen,3)
(and,269)
(TNBC 
Recent,1)
(motility,1)
(lower,4)
(PsycInfo,,1)
(reduce,3)
(reviewers,1)
(modifications,,1)
